Acer Therapeutics Inc.
(NASDAQ CM: ACER)
Rigrodsky Law, P.A. is investigating Acer Therapeutics Inc. (“Acer”) regarding possible breaches of fiduciary duties and other violations of law related to Acer’s agreement to be acquired by Zevra Therapeutics, Inc. (“Zevra”). Under the terms of the agreement, Acer shareholders will receive 0.121 shares of Zevra’s common stock for each share of Acer’s common stock owned.